Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Open accessPublished version of a preprint
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4+ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients. Cancer Res; 71(3); 661–5. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The chemotherapeutic agent, cyclophosphamide, was shown to alter intestinal microbiota in mice and promote “pathogenic” Th17 cell production [422]; however, removing gut microbiota via antibiotic treatment led to drug resistance [423, 424].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [424]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationRegulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Self-citationWei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, T.-Y., Watford, W. T., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.009 · Cited by 1,152
Molecular Antagonism and Plasticity of Regulatory and Inflammatory T Cell Programs
Yang, X. O., Nurieva, R., Martinez, G. J., Kang, H. S., Chung, Y., Pappu, B. P., Shah, B., Chang, S. H., Schluns, K. S., Watowich, S. S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.007 · Cited by 1,136
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17–producing cells
Koenen, H. J. P. M., Smeets, R. L., Vink, P. M., van Rijssen, E., Boots, A. M. H., & Joosten, I. (2008) · Blood · doi:10.1182/blood-2008-01-133967 · Cited by 736
Identification of IL-17-producing FOXP3+regulatory T cells in humans
Voo, K. S., Wang, Y.-H., Santori, F. R., Boggiano, C., Wang, Y.-H., Arima, K., Bover, L., Hanabuchi, S., Khalili, J., Marinova, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900408106 · Cited by 689
IL-17–producing human peripheral regulatory T cells retain suppressive function
Beriou, G., Costantino, C. M., Ashley, C. W., Yang, L., Kuchroo, V. K., Baecher-Allan, C., & Hafler, D. A. (2009) · Blood · doi:10.1182/blood-2008-10-183251 · Cited by 483
Cited by
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Self-citationImmunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Self-citationPitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
Self-citationRadiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Metadata
- Authors
- Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., Chaput, N., & Zitvogel, L.
- Affiliations
- Université Paris-Sud (FR)
- Authors' Affiliations: 1Faculté de Médecine de l'Université Paris-Sud XI, Le Kremlin-Bicêtre, France; 2Institut National de la Santé et de la Recherche Médicale, U1015; 3Institut de Cancérologie Gustave Roussy; 4Center of Clinical Investigations in Biotherapies of Cancer CICBT 507; 5Service Innovations Thérapeutiques Essais Précoces (SITEP), 6Department of Medicine, 7Laboratory of Translational Research, 8Department of Dermatology, and 9Cell Therapy Unit, Institut de Cancérologie Gustave Roussy, Villejuif, France
- Corresponding author
- Chaput, Nathalie
- Zitvogel, Laurence
- ORCID
- Venue
- Cancer Research
- Published
- 2011-02-01
- Volume
- 71
- Issue
- 3
- Pages
- 661-665
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2145291973
- Cited by
- 170
- References
- 20
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 15 · 2023: 15 · 2022: 10 · 2021: 9 · 2020: 11 · 2019: 11 · 2018: 11 · 2017: 10 · 2016: 9 · 2015: 8 · 2014: 16 · 2013: 13 · 2012: 11
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Washington
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cyclophosphamide, Th17 cells, CD4+ T cells, regulatory T cells, alkylating agents, immunotherapy, tumor immunology, antiangiogenic activity, tumor-infiltrating lymphocytes, autoimmunity, inflammation
- MeSH terms
- Imatinib Mesylate, Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Cell Differentiation, Cyclophosphamide, Female, Humans, Interleukin-2, Male, Melanoma, Experimental, Mice, Inbred C57BL, Middle Aged, Neoplasms, Piperazines, Pyrimidines, Lymphocyte Subsets, Antineoplastic Agents, Alkylating, T-Lymphocytes, Regulatory, Mice, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-1259
- The paper
- Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., Chaput, N., & Zitvogel, L. (2011). Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-1259
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.